Expert of the Month Interviews

Gene Therapy in Hemophilia experts from around the world provide updates monthly on the latest information and news.

This Month's Video: Five Year Data Confirms Stable FIX Expression and Sustained Reductions in Bleeding and Factor IX Use Following AMT-060 Gene Therapy in Adults with Severe or Moderate-severe Hemophilia B

Presented by: Wolfgang A. Miesbach, MD, PhD, Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Goethe University Hospital, Frankfurt/Main Germany.

Additional Updates

What to Expect at the upcoming ISTH Congress in Gene Therapy Hemophilia

Presented by: David Lillicrap, MD, FRCPC, Department of Pathology & Molecular Medicine, Queen's University, Kingston, Ontario

Highlights from the ASGCT 24th Annual Meeting

Presented by: Wolfgang A. Miesbach, MD, PhD, Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Goethe University Hospital, Frankfurt/Main Germany.

Hepatoxicity and Gene Therapy
 

Presented by: Guy Young, MD, Director, Hemostasis and Thrombosis Program, Professor of Pediatrics (Clinical Scholar), Keck School of Medicine of USC, Los Angeles, California.

Durability: Factor VIII and Factor IX Differences

Presented by: Guy Young, MD, Director, Hemostasis and Thrombosis Program, Professor of Pediatrics (Clinical Scholar), Keck School of Medicine of USC, Los Angeles, California.